Physician profile
Kelly Fallin
NPI 1720376957
$9,455.26
in general payments reported to CMS, 2019-2025
18 companies · $649 in 2025
The $649 reported for 2025 was more than what 83% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,076 · 2020: $5,145 · 2021: $798 · 2022: $737 · 2023: $626 · 2024: $424 · 2025: $649.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,699.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,699.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $5,939.35 | 2019-2025 | Myday Contact Lens, Clariti Contact Lens, Misight Contact Lens |
| Alcon Vision LLC | $1,205.25 | 2019-2025 | Precision 1 |
| Biotissue Holdings INC. | $696.52 | 2019-2025 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $317.56 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $292.72 | 2019-2025 | Cequa |
| Johnson & Johnson Vision Care, INC. | $269.84 | 2019-2022 | |
| Abb Con-Cise Optical Group LLC | $121.06 | 2019-2021 | |
| Allergan, INC. | $117.16 | 2019-2022 | |
| Aerie Pharmaceuticals, INC. | $99.98 | 2019 | |
| Oyster Point Pharma, INC. | $97.75 | 2022-2023 | Tyrvaya |
| Bausch & Lomb Americas INC. | $59.75 | 2023-2024 | Miebo, Vyzulta, Xiidra |
| Tarsus Pharmaceuticals, INC. | $48.27 | 2024-2025 | Xdemvy |
| Novartis Pharmaceuticals Corporation | $41.10 | 2021-2023 | |
| Abbvie INC. | $35.96 | 2024-2025 | |
| Kala Pharmaceuticals, INC. | $33.26 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $28.32 | 2019 | |
| Horizon Therapeutics Plc | $27.92 | 2023 | Tepezza |
| Maculogix, INC. | $23.49 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kelly Fallin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.